Drug Development and PET-Diagnostics for Alzheimers Disease

Title: Drug Development and PET-Diagnostics for Alzheimers Disease

Volume: 12 Issue: 14

Author(s): Boris Schmidt, Hannes A. Braun and Rajeshwar Narlawar

Affiliation:

Keywords: alzheimers disease, secretase, copper, statine, aspartic protease, cholesterol, imaging

Abstract: The exact cause of Alzheimers disease is still unknown; despite the dramatic progress in understanding. Most gene mutations associated with Alzheimers disease point to the amyloid precursor protein and amyloid β. The α-, β- and γ-secretases are the three executioners of amyloid precursor protein processing. Significant progress has been made in the selective inhibition of these proteases, regardless of the availability of structural information. Several peptidic and non-peptidic leads were identified and first drug candidates are in clinical trials. Cholesterol lowering drugs and metal chelators are also in advanced clinical stages as disease modifiers. Successful trials demand either large cohorts or reliable markers for Alzheimers disease. Therefore, several radiomarkers are under investigation to support such clinical trials.

Cite this article as:

Schmidt Boris, Braun A. Hannes and Narlawar Rajeshwar, Drug Development and PET-Diagnostics for Alzheimers Disease, Current Medicinal Chemistry 2005; 12 (14) . https://dx.doi.org/10.2174/0929867054367130